Biotech co. developing psychedelics for medical use starts trading on NASDAQ
Atai CEO and co-founder Florian Brand on his biotech company going public.
Friday, June 18, 2021
Biotech co. developing psychedelics for medical use starts trading on NASDAQ
Biotech co. developing psychedelics for medical use starts trading on NASDAQ
Atai CEO and co-founder Florian Brand on his biotech company going public.
Related Posts:
U.S. FAA says handling aircraft approval on its own would cost $1.8 billion- U.S. FAA says it has not granted initial approval for Boeing 737 MAX anti-stall upgrade
- Boeing rolls out software fix to defend 737 MAX franchise, awaits U.S. regulator's approval
- New Jersey jury finds J&J not liable in talc cancer trial; company settles three other cases
- Wall Street ends down as Treasury yields fall on slowdown worries
0 comments:
Post a Comment